STAAR Surgical Company Reports Third Quarter 2012 Financial Results
Published: Nov 01, 2012
MONROVIA, Calif., Oct. 31, 2012 /PRNewswire/ -- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today reported that sales of its Visian ICL product portfolio in the third quarter ended September 28, 2012 increased 15% to $9.1 million. Total revenue was $15.9 million, up 4% from $15.3 million in the third quarter of 2011. Gross margin of 70.4% was 190 basis points above the 68.5% margin in the third quarter of 2011. The year over year gross margin improvement continues to reflect the increased contribution of Visian ICL sales, margin improvement in ICLs based on increased prices and lower cost of goods for both ICLs and IOLs.